此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

使用基因组肿瘤委员会是否会增加接受基因组信息治疗的患者数量

2026年11月10日 更新者:SWOG Cancer Research Network

比较教育增强型基因组肿瘤委员会 (EGTB) 干预与常规做法以增加循证基因组知情治疗的整群随机试验

This clinical trial studies how well an educationally enhanced genomic tumor board (EGTB) intervention works to increase the number of patients with solid tumors that have come back (recurrent), do not respond to treatment (refractory), have spread to other parts of the body (metastatic), or are newly diagnosed and spread to other parts of the body (advanced) who receive genome-informed treatment. Genome-informed treatment refers to treatment based on the information found in genomic tumor test results. This study compares the usual approach to reviewing genomic tumor test results with the approach of having a genomic tumor board (GTB) review the test results. A GTB is team of doctors and scientists that have experience in understanding genomic changes and review genomic tumor test results. The tumor board helps to suggest whether there are other cancer treatment options based on patient genetic test results. The usual approach is to review genomic tumor test results without the GTB being involved. This study may help researchers learn if using a GTB enhances the treatment decision making process within 6 months of joining the study. This study may also help researchers learn if using the GTB increases doctors' understanding of genomic tumor test results and increases doctors' comfort level with genomic tumor tests.

研究概览

详细说明

PRIMARY OBJECTIVE:

I. To determine whether an EGTB intervention compared to usual practice increases the proportion of patients who receive evidence-based genome-informed therapy within 6 months after registration to the study.

SECONDARY OBJECTIVES:

I. To compare physician genomic confidence and physician experience with genomic tumor testing (GTT) between arms at baseline and end of study.

II. To compare clinical outcomes between arms by assessing patient survival and time to treatment discontinuation.

III. To compare physician assessment of evidence-based genome-informed therapy to the central study team determination of evidence-based genome-informed therapy, both overall and separately by arm.

IMPLEMENTATION OBJECTIVES:

I. To assess the utilization of GTT and implementation of the EGTB intervention into clinic workflow in order to better understand barriers and facilitators at Recruitment Centers assigned to the active intervention arm using a mixed-methods approach.

II. To assess the evolution of GTT utilization within clinic workflows at recruitment centers assigned to the usual practice (control) arm using a mixed-methods approach.

OUTLINE: Study clinics are randomized to 1 of 2 arms. Participants receive interventions based on this randomization.

ARM 1: Participants receive usual care. This consists of physicians ordering GTT for patients and reviewing the results without the GTB being involved.

ARM 2: Patients and physicians receive the EGTB intervention. This is comprised of 2 components: the structured GTB and the supporting education. Physicians submit cases for discussion to the GTB within 2 weeks of GTT results. The GTB sessions are held weekly and conducted virtually over a video-conferencing platform. Each case presentation is 10 to 15 minutes long, and 4 to 6 cases are discussed during each 60 minute GTB session. GTT results and clinical data are presented and expert interpretation of genomic test results is provided to help prioritize potential treatment options and provide a framework for interpretation. Supporting education materials are also available online to participants to support GTT decision making.

Physicians are followed until the end of the study or through 6 months after their last patient was registered to the study, whichever is later. Patients are followed for 24 months after registration or until a criterion for removal from protocol participation is met, whichever comes first.

研究类型

介入性

注册 (实际的)

1284

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Manati、波多黎各、00674
        • Doctors Cancer Center
      • San Juan、波多黎各、00927
        • Centro Comprensivo de Cancer de UPR
    • Arizona
      • Phoenix、Arizona、美国、85004
        • Cancer Center at Saint Joseph's
    • Georgia
      • Savannah、Georgia、美国、31405
        • Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
    • Hawaii
      • Honolulu、Hawaii、美国、96813
        • Queen's Medical Center
      • Honolulu、Hawaii、美国、96813
        • Hawaii Cancer Care Inc - Waterfront Plaza
      • Honolulu、Hawaii、美国、96813
        • Straub Clinic and Hospital
      • Honolulu、Hawaii、美国、96813
        • University of Hawaii Cancer Center
      • Honolulu、Hawaii、美国、96826
        • Kapiolani Medical Center for Women and Children
      • ‘Aiea、Hawaii、美国、96701
        • Hawaii Cancer Care - Westridge
      • ‘Aiea、Hawaii、美国、96701
        • Pali Momi Medical Center
    • Idaho
      • Post Falls、Idaho、美国、83854
        • Kootenai Clinic Cancer Services - Post Falls
    • Illinois
      • Bloomington、Illinois、美国、61704
        • Illinois CancerCare-Bloomington
      • Canton、Illinois、美国、61520
        • Illinois CancerCare-Canton
      • Danville、Illinois、美国、61832
        • Carle at The Riverfront
      • Galesburg、Illinois、美国、61401
        • Illinois CancerCare-Galesburg
      • Mattoon、Illinois、美国、61938
        • Carle Physician Group-Mattoon/Charleston
      • Ottawa、Illinois、美国、61350
        • Illinois CancerCare-Ottawa Clinic
      • Peoria、Illinois、美国、61615
        • Illinois CancerCare-Peoria
      • Urbana、Illinois、美国、61801
        • Carle Cancer Center
    • Iowa
      • Des Moines、Iowa、美国、50309
        • Iowa Methodist Medical Center
      • Des Moines、Iowa、美国、50309
        • Medical Oncology and Hematology Associates-Des Moines
    • Kansas
      • Hays、Kansas、美国、67601
        • HaysMed University of Kansas Health System
      • Lawrence、Kansas、美国、66044
        • Lawrence Memorial Hospital
      • Olathe、Kansas、美国、66061
        • Olathe Health Cancer Center
      • Overland Park、Kansas、美国、66210
        • University of Kansas Cancer Center-Overland Park
      • Salina、Kansas、美国、67401
        • Salina Regional Health Center
      • Topeka、Kansas、美国、66606
        • University of Kansas Health System Saint Francis Campus
    • Kentucky
      • Lexington、Kentucky、美国、40509
        • Saint Joseph Hospital East
      • London、Kentucky、美国、40741
        • Saint Joseph London
    • Michigan
      • Ann Arbor、Michigan、美国、48106
        • Saint Joseph Mercy Hospital
      • Brighton、Michigan、美国、48114
        • Saint Joseph Mercy Brighton
      • Chelsea、Michigan、美国、48118
        • Saint Joseph Mercy Chelsea
      • Detroit、Michigan、美国、48236
        • Ascension Saint John Hospital
      • Livonia、Michigan、美国、48154
        • Trinity Health Saint Mary Mercy Livonia Hospital
      • Pontiac、Michigan、美国、48341
        • Saint Joseph Mercy Oakland
    • Minnesota
      • Brainerd、Minnesota、美国、56401
        • Essentia Health Saint Joseph's Medical Center
      • Burnsville、Minnesota、美国、55337
        • Minnesota Oncology - Burnsville
      • Coon Rapids、Minnesota、美国、55433
        • Mercy Hospital
      • Duluth、Minnesota、美国、55805
        • Essentia Health Cancer Center
      • Fridley、Minnesota、美国、55432
        • Unity Hospital
      • Maplewood、Minnesota、美国、55109
        • Saint John's Hospital - Healtheast
      • New Ulm、Minnesota、美国、56073
        • New Ulm Medical Center
      • Saint Louis Park、Minnesota、美国、55416
        • Park Nicollet Clinic - Saint Louis Park
      • Saint Paul、Minnesota、美国、55101
        • Regions Hospital
      • Stillwater、Minnesota、美国、55082
        • Lakeview Hospital
      • Waconia、Minnesota、美国、55387
        • Ridgeview Medical Center
      • Woodbury、Minnesota、美国、55125
        • Minnesota Oncology Hematology PA-Woodbury
      • Wyoming、Minnesota、美国、55092
        • Fairview Lakes Medical Center
    • Missouri
      • Farmington、Missouri、美国、63640
        • Parkland Health Center - Farmington
      • Kansas City、Missouri、美国、64154
        • University of Kansas Cancer Center - North
      • Kansas City、Missouri、美国、64108
        • Truman Medical Centers
      • Lee's Summit、Missouri、美国、64064
        • University of Kansas Cancer Center - Lee's Summit
      • North Kansas City、Missouri、美国、64116
        • University of Kansas Cancer Center at North Kansas City Hospital
      • Rolla、Missouri、美国、65401
        • Delbert Day Cancer Institute at PCRMC
      • Sainte Genevieve、Missouri、美国、63670
        • Sainte Genevieve County Memorial Hospital
      • Springfield、Missouri、美国、65807
        • CoxHealth South Hospital
      • St Louis、Missouri、美国、63131
        • Missouri Baptist Medical Center
      • Sullivan、Missouri、美国、63080
        • Missouri Baptist Sullivan Hospital
      • Sunset Hills、Missouri、美国、63127
        • Missouri Baptist Outpatient Center-Sunset Hills
    • North Carolina
      • Pinehurst、North Carolina、美国、28374
        • FirstHealth of the Carolinas-Moore Regional Hospital
    • North Dakota
      • Fargo、North Dakota、美国、58103
        • Essentia Health Cancer Center-South University Clinic
    • Pennsylvania
      • Allentown、Pennsylvania、美国、18103
        • Lehigh Valley Hospital-Cedar Crest
    • South Carolina
      • Bluffton、South Carolina、美国、29910
        • Saint Joseph's/Candler - Bluffton Campus
      • Gaffney、South Carolina、美国、29341
        • Gibbs Cancer Center-Gaffney
      • Greer、South Carolina、美国、29651
        • Gibbs Cancer Center-Pelham
      • Spartanburg、South Carolina、美国、29303
        • Spartanburg Medical Center
      • Union、South Carolina、美国、29379
        • MGC Hematology Oncology-Union
    • Wisconsin
      • Brookfield、Wisconsin、美国、53045
        • Ascension Southeast Wisconsin Hospital - Elmbrook Campus
      • Franklin、Wisconsin、美国、53132
        • Ascension Saint Francis - Reiman Cancer Center
      • Mequon、Wisconsin、美国、53097
        • Ascension Columbia Saint Mary's Hospital Ozaukee
      • Wauwatosa、Wisconsin、美国、53226
        • Ascension Medical Group Southeast Wisconsin - Mayfair Road

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • RECRUITMENT CENTERS INCLUSION

  • A Recruitment Center is defined as an outpatient clinic, or group of clinics, belonging to the same National Cancer Institute Community Oncology Research Program (NCORP) or minority/underserved (MU)-NCORP, who will be contributing physicians and patient participants to the study

  • Recruitment Centers must be part of an NCORP or MU-NCORP site with Cancer Care Delivery Research (CCDR) funding as this study is supported by CCDR funding. Each clinic included in the Recruitment Center must be associated with Cancer Therapy Evaluation Program (CTEP) site identification (ID).

  • Recruitment Centers must send large panel next generation sequencing genomic tests on at least 10 unique patients per month.

  • Recruitment Centers must have at least 4 practicing oncologists (including medical, gynecologic, or neuro-oncologists) at the site willing to participate in the study and register within three months of study activation.

  • Recruitment Centers must be willing to register a total of 66 patients (over 2 years) to the study.

  • Centers must be able to send at least one member of the study team to attend the Recruitment Center's cases presented to the S2108CD Genomic Tumor Board, should the Recruitment Center be randomized to the intervention arm.

  • Recruitment Centers must be willing and able to document the number of unique patients on which GTT is ordered at the Recruitment Center and submit this monthly to the S2108CD Study Team.

  • PHYSICIAN PARTICIPANT INCLUSION

  • Physician participant must be a registering investigator of the Recruitment Center that is participating in the study. If the physician is a registering investigator at more than one Recruitment Center, he/she must choose one Recruitment Center to identify with and enroll patients from.

  • Physician participants must be board-eligible or board-certified in Medical Oncology, Gynecologic Oncology, or Neurology with certification or eligible for certification in Neuro-oncology.

  • Physician participants must be willing to offer participation in the study to all eligible patients under their care for the duration of the study. A single physician may enroll multiple patients on the study.

  • Physician participants must be willing to complete all study questionnaires and, as part of the implementation objective, participate in interviews if invited.

  • Physician participants must complete all baseline questionnaires prior to registration.

  • Physician participants at a Recruitment Center randomized to the intervention arm must be willing to participate in the educationally enhanced GTB (EGTB).

  • PATIENT PARTICIPANT INCLUSION

  • Patient participants must have either recurrent, relapsed, refractory, metastatic, or newly diagnosed advanced stage III or stage IV solid tumor malignancy.

  • Patient participants must be under the care of a physician enrolled on the study.

  • Patient participants may have started anti-cancer treatment for the current diagnosis. The treating physician anticipates that the patient will start a new anti-cancer treatment (either first or subsequent lines) within 6 months after registration.

  • Patient participants are allowed to be co-enrolled on other clinical trials including non-treatment studies and studies that include investigational drugs. Patients may be enrolled on genome-informed therapeutic trials, such as LungMAP, MATCH, TAPUR, etc.

  • Patient participants' genomic tumor test must have been ordered within 7 days prior to registration with results pending. The genomic testing may be a commercially available panel (such as FoundationOne, Caris, Tempus, etc.) or a non-commercial tumor panel performed at an academic medical center.

    • NOTE: Qualifying GTTs are defined as Clinical Laboratory Improvement Act (CLIA)-certified next generation sequencing (NGS) tissue or liquid biopsy panels, including hotspot, whole gene, deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) (including expression data) panels. Fluorescence-in-situ hybridization (FISH) and immunohistochemistry test results assessing cancer-relevant proteins (e.g. Her2/neu, ALK, MET) and immune parameters (e.g. PD-L1 tests) are also permissible if performed in the context of a larger panel that includes NGS or expression profiling. These tests can come from any commercial or academic laboratory within the United States (US) and they should be ordered with the intent to influence genome-informed treatment decision. Oncotype DX and other panels used for making treatment decisions based on a prognostic read-out (e.g. liquid biopsy minimal residual disease [MRD]) are not permitted.
  • Patient participants must be at least 18 years of age.

  • Patient participants must have a Zubrod performance status of 0-2.

  • Participants (patients and physicians) must sign and give written informed consent in accordance with institutional and federal guidelines. For patient participants with impaired decision-making capabilities, legally authorized representative may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations. Documentation of informed consent via remote consent is permissible.

Exclusion Criteria:

  • RECRUITMENT CENTERS EXCLUSION
  • Recruitment Centers must not have or utilize an existing Genomic Tumor Board (GTB). For the purposes of this study, a Genomic Tumor Board is defined as an interdisciplinary team of clinicians and scientists that reviews genomic testing results and provides guidance on treatment options based primarily on genomic data to the treating physician. The existence of a general multidisciplinary tumor board that addresses all aspects of patient care and treatment is not considered an exclusion criterion. A general multidisciplinary tumor board is defined as an interdisciplinary team of clinicians that primarily discusses all aspects of cancer care, including diagnostic aspects (pathology and radiology), therapeutic options (surgical, radiation and medical) as well as palliative and psychosocial support options.
  • PATIENT PARTICIPANT EXCLUSION
  • Patient participants must not be going on hospice care at the time of registration.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:卫生服务研究
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
有源比较器:Arm 1 (usual care)

Participants receive usual care. This consists of physicians ordering GTT for patients and reviewing the results without the GTB being involved.

Ancillary studies

Ancillary studies

Receive usual care

其他名称:
  • 护理标准
  • 标准疗法

Ancillary studies

Patients undergo genomic testing

其他名称:
  • 遗传概况
  • 基因组概况
  • 基因组分析
  • 基因组测试
  • 基因组检测
实验性的:Arm 2 (EGTB)

Patients and physicians receive the EGTB intervention. This is comprised of 2 components: the structured GTB and the supporting education. Physicians submit cases for discussion to the GTB within 2 weeks of GTT results. The GTB sessions are held weekly and conducted virtually over a video-conferencing platform. Each case presentation is 10 to 15 minutes long, and 4 to 6 cases are discussed during each 60 minute GTB session. GTT results and clinical data are presented and expert interpretation of genomic test results is provided to help prioritize potential treatment options and provide a framework for interpretation. Supporting education materials are also available online to participants to support GTT decision making.

Ancillary studies

Ancillary studies

Ancillary studies

Patients undergo genomic testing

其他名称:
  • 遗传概况
  • 基因组概况
  • 基因组分析
  • 基因组测试
  • 基因组检测

Physicians access genomic testing education materials

其他名称:
  • 干预教育
  • 教育干预
  • 通过教育进行干预
  • 干预,教育

Patients undergo genomic tumor board review

其他名称:
  • 多学科意见

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Percent of patients who receive a treatment that targets a genomic variant for which there is sufficient data to support actionability
大体时间:Within 6 months of study completion

Evidence-based genome-informed therapy is defined as the use of a treatment that targets a genomic variant for which there is sufficient data to support actionability. This is a patient-specific measure determined through blinded central review of patient data, following the schemas in the protocol. An independent panel of investigators blinded to the study arm assignment of the study participant will evaluate redacted data from each subject for determination of the primary endpoint. Data supporting the primary endpoint are obtained from the genomic tumor test results PDF, pathology report, primary tumor type, and the S2108CD Treatment Form as well as curated evidence plus evidence level (tier) designation from the Jackson Labs Clinical Knowledge Base.

Within 6 months of study completion

次要结果测量

结果测量
措施说明
大体时间
Physician genomic confidence
大体时间:Baseline and month 27 after study activation

Measured by 3-item scale assessing physician confidence in genomic knowledge and ability to explain genomic concepts/make treatment recommendations. This assessment is on the S2108CD Genomic Testing Questionnaire.

Baseline and month 27 after study activation
Physician experience using genomic tumor testing (GTT) in practice
大体时间:Baseline and month 27 after study activation

The physician experience using genomic tumor testing in practice will be assessed using selected items from the National Survey of Precision Medicine in Cancer Treatment, included on the S2108CD Genomic Testing Questionnaire.

Baseline and month 27 after study activation
Overall survival
大体时间:From registration until death due to any cause, assessed up to 24 months

Overall survival on study will be measured from registration until death due to any cause.

From registration until death due to any cause, assessed up to 24 months
Overall survival on new anticancer therapy
大体时间:From the time new anticancer therapy is initiated on study until deathdue to any cause, assessed up to 24 months

Overall survival on new anticancer therapy will be measured from the time new anticancer therapy is initiated on study until death due to any cause.

From the time new anticancer therapy is initiated on study until deathdue to any cause, assessed up to 24 months
Time to treatment discontinuation
大体时间:From registration until the last dose recorded or death, assessed up to 24 months

Time to treatment discontinuation on study will be measured as the time from registration until the last dose recorded or death.

From registration until the last dose recorded or death, assessed up to 24 months
Time to treatment discontinuation on new anticancer therapy
大体时间:From registration until the last dose recorded or death, assessed up to 24 months

time to treatment discontinuation on new anticancer therapy will be measured as the time from registration until the last dose recorded or death.

From registration until the last dose recorded or death, assessed up to 24 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Jens Rueter、SWOG Cancer Research Network

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2022年10月14日

初级完成 (估计的)

2027年3月1日

研究完成 (估计的)

2027年3月1日

研究注册日期

首次提交

2022年7月6日

首先提交符合 QC 标准的

2022年7月12日

首次发布 (实际的)

2022年7月13日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年1月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅